CAS |
151767-02-1 |
Chinese Name |
孟鲁司特钠 |
English Name |
Montelukast Sodium |
Unit |
Bottle |
Purity |
HPLC≥98% |
Molecular Formula |
C35H35ClNNaO3S |
Molecular Weight |
608.17 |
Appearance |
White to off-white solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥50mg/ml, soluble in water≥10mg/ml |
EC |
EINECS 604-813-7 |
MDL |
MFCD00931431 |
InChIKey |
LBFBRXGCXUHRJY-HKHDRNBDSA-M |
InChI |
InChI=1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1 |
PubChem CID |
23663996 |
Delivery Time |
1-2 days |
SMILES |
ClC1=CC2=C(C=C1)C=CC(/C=C/C3=CC([C@H](SCC4(CC([O-])=O)CC4)CCC5=CC=CC=C5C(C)(O)C)=CC=C3)=N2.[Na+] |
Description |
Montelukast sodium is a potent, selective leukotriene receptor antagonist. |
Target Point |
Leukotriene Receptor |
Passage |
GPCR & G Protein |
Data Literature Source |
[1]. Mullol J, et al. Montelukast?reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J Biol Regul Homeost Agents.?2010 Oct-Dec;24(4):403-11.
[2]. Zhang HP, et al. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Allergy Asthma Proc. 2014 Jul-Aug;35(4):278-87.
[3]. Wei B, et al. Effect of montelukast on the expression of neurokinin-1 receptor in young asthmatic rats with airway remodeling. Zhongguo Dang Dai Er Ke Za Zhi. 2013 Apr;15(4):298-301.
[4]. Lai J, et al. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology. 2014 Apr;79:707-14 |
Specification |
50mg 10mM*1mL in Water 100mg 500mg |